Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Meta-review: adverse effects of inhaled corticosteroids relevant to older patients.

Mattishent K, Thavarajah M, Blanco P, Gilbert D, Wilson AM, Loke YK.

Drugs. 2014 Apr;74(5):539-47. doi: 10.1007/s40265-014-0202-z. Review.

PMID:
24659375
2.

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.

Kew KM, Seniukovich A.

Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115. doi: 10.1002/14651858.CD010115.pub2. Review.

PMID:
24615270
3.

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies.

Loke YK, Cavallazzi R, Singh S.

Thorax. 2011 Aug;66(8):699-708. doi: 10.1136/thx.2011.160028. Review.

PMID:
21602540
4.

Inhaled corticosteroids in children with persistent asthma: effects on growth.

Zhang L, Prietsch SO, Ducharme FM.

Evid Based Child Health. 2014 Dec;9(4):829-930. doi: 10.1002/ebch.1988.

PMID:
25504972
5.

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E.

JAMA. 2008 Nov 26;300(20):2407-16. doi: 10.1001/jama.2008.717. Review. Erratum in: JAMA. 2009 Mar 11;301(10):1024.

6.

Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth.

Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM.

Evid Based Child Health. 2014 Dec;9(4):931-1046. doi: 10.1002/ebch.1989.

PMID:
25504973
7.

Inhaled corticosteroids in COPD and the risk of serious pneumonia.

Suissa S, Patenaude V, Lapi F, Ernst P.

Thorax. 2013 Nov;68(11):1029-36. doi: 10.1136/thoraxjnl-2012-202872.

8.

Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.

Liapikou A, Toumbis M, Torres A.

Expert Opin Drug Saf. 2015 Aug;14(8):1237-47. doi: 10.1517/14740338.2015.1057494. Review.

PMID:
26113207
9.

Ciclesonide versus other inhaled corticosteroids for chronic asthma in children.

Kramer S, Rottier BL, Scholten RJ, Boluyt N.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD010352. doi: 10.1002/14651858.CD010352. Review.

PMID:
23450613
10.

Inhaled corticosteroids for stable chronic obstructive pulmonary disease.

Yang IA, Clarke MS, Sim EH, Fong KM.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002991. doi: 10.1002/14651858.CD002991.pub3. Review.

PMID:
22786484
11.

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.

Kew KM, Dias S, Cates CJ.

Cochrane Database Syst Rev. 2014 Mar 26;(3):CD010844. doi: 10.1002/14651858.CD010844.pub2. Review.

PMID:
24671923
12.

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.

Latorre M, Novelli F, Vagaggini B, Braido F, Papi A, Sanduzzi A, Santus P, Scichilone N, Paggiaro P.

Pulm Pharmacol Ther. 2015 Feb;30:44-50. doi: 10.1016/j.pupt.2014.10.006. Review.

PMID:
25445928
13.

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.

Nannini LJ, Poole P, Milan SJ, Kesterton A.

Cochrane Database Syst Rev. 2013 Aug 30;(8):CD006826. doi: 10.1002/14651858.CD006826.pub2. Review.

PMID:
23990350
14.

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.

Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, Liu Z, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. Review.

15.

Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis.

Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R.

Respirology. 2009 Sep;14(7):983-90. doi: 10.1111/j.1440-1843.2009.01589.x. Review.

PMID:
19740259
16.

Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects.

Christensson C, Thorén A, Lindberg B.

Drug Saf. 2008;31(11):965-88. Review.

PMID:
18840017
17.

Safety of the newer inhaled corticosteroids in childhood asthma.

Randell TL, Donaghue KC, Ambler GR, Cowell CT, Fitzgerald DA, van Asperen PP.

Paediatr Drugs. 2003;5(7):481-504. Review.

PMID:
12837120
18.

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.

Main C, Shepherd J, Anderson R, Rogers G, Thompson-Coon J, Liu Z, Hartwell D, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(20):1-174, iii-iv. Review.

19.

Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis.

Etminan M, Sadatsafavi M, Ganjizadeh Zavareh S, Takkouche B, FitzGerald JM.

Drug Saf. 2008;31(5):409-14. Review.

PMID:
18422381
20.

Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis.

Flynn RW, MacDonald TM, Hapca A, MacKenzie IS, Schembri S.

Respir Res. 2014 Nov 19;15:141. doi: 10.1186/s12931-014-0141-y.

Items per page

Supplemental Content

Support Center